Sirtex Medical is not FDA approved for HCC which this study was on.
Looks like they will get a new FDA label to HCC but will have to wait for the results from SIRveNIB study on the 6th June and the subgroup analysis.
Many people speculated that the SARAH study, reported today, was going to miss it's primary endpoint as the group of patients was too mixed.
The FOXFIRE and SIRveNIB study results will most likely have hits on success for their primary endpoints.
Sirt result, page-4
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.003(1.64%) |
Mkt cap ! $65.79M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.5¢ | 15.5¢ | $1.707K | 11.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 288988 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 2531639 | 22 |
View Market Depth
| Last trade - 10.59am 11/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |